Oct 25, 202631 min
Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
About this Podcast:
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Pitch Analysis
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
38%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for The Uromigos.
Signup to Generate a PitchQuestions about The Uromigos
What is The Uromigos about?
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
What has The Uromigos covered recently?
Recent episodes include "Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival" (25 October 2026, 31 minutes), "Episode 528: ESMO 2026 - LITESPARK 012" (25 October 2026, 44 minutes), and "Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer" (24 October 2026, 38 minutes).
How often does The Uromigos publish?
The Uromigos publishes roughly daily, with episodes averaging 37 minutes across 495 episodes.
How hard is it to get booked on The Uromigos?
Booking probability for The Uromigos is 38%, and the host is rated Selective on guests. The Uromigos requires a Pod Score of 80 or higher. The Uromigos's contact route on record: verified email.
Who should pitch The Uromigos?
The strongest fits for The Uromigos are Doctors & Physicians and Health & Wellness Services. The Uromigos has a health audience.
About the host
The Uromigos is a health podcast with 495 episodes published.
Verified host email: ████████@████.comSign in to unlock →
Recent episodes
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
The Uromigos
Episode 528: ESMO 2026 - LITESPARK 012
Oct 25, 202644 minMartin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
- Oct 24, 202638 min
Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
The Uromigos
Episode 526: ESMO 2026 - The VOLGA trial in MIBC
Oct 24, 202637 minMichiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
- Oct 24, 202647 min
Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC
View More
- Oct 24, 202616 min
Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell...
- Oct 23, 202636 min
Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
- Oct 23, 202624 min
Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.
The Uromigos
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Oct 23, 202633 minRob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of...
The Uromigos
Episode 520: ESMO 2026 Preview
Oct 12, 202655 minSilke, Brian and Tom preview the major data to be presented at ESMO 2026
- Oct 5, 202633 min
Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).
- Aug 31, 202641 min
Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
- Aug 17, 202648 min
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.
- Aug 3, 202643 min
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.
- Jul 20, 202640 min
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
- Jul 13, 202626 min
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
- Jul 6, 202631 min
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
The Uromigos
Episode 510: ADCs in Prostate Cancer
Jun 15, 202630 minTanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and...
The Uromigos
Episode 509: ASCO 2026 Review
Jun 8, 202655 minThis comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent...
The Uromigos
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
May 31, 202640 minMary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Recent guests
Recent guests on The Uromigos. Study who booked and why before you pitch.
R
Rob Jones
Marine Corps Veteran, US Paralympic Medalist, ultra-endurance athlete, congressional candidate in the 10th district of Virginia, Sarasota Spine & Sports Performance
D
Dr. Travis Zack
oncologist, assistant professor at UCSF, Open Evidence
L
Louise Emmett
Director of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney
M
Michael Morris
Chavkin-Chang Professor of Leadership at Columbia Business School, North Central Texas Council of Governments
Best industries to pitch The Uromigos for
PitchCentric classifies The Uromigos under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Similar Podcasts
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Podcasts like The Uromigos
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ